Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry
Aesthetics Market トレンド
美的市場は現在、技術の進歩と消費者の嗜好の変化によってダイナミックな進化を遂げています。個人がセルフケアや身だしなみをますます重視するようになるにつれ、美容処置や製品に対する需要が高まり続けています。世界の医療美容市場は、再生治療と AI を活用したパーソナライゼーションが患者ケアの新しい標準となるにつれて急速に拡大しています。
ZO Skin Health Inc. - 7 月 2024: ZO Skin Healthは、ひげそりの炎症、ニキビ、老化の兆候などの一般的な男性の肌の悩みに対処する、男性向けに特別に設計された新しいスキンケア製品ラインを発売しました。このラインは、抗炎症作用と保湿作用が強化された高度な処方を特徴としています。これらの製品には、さまざまな肌のタイプや状態に適応する独自のテクノロジーが組み込まれており、男性の肌の健康に合わせたソリューションを提供します。
An accomplished research analyst with high proficiency in market forecasting, data visualization, competitive benchmarking, and others. He holds a pronounced track record in research and consulting projects for sectors such as life sciences, medical devices, and healthcare IT. His capabilities in qualitative and quantitative analysis have resulted in positive client outcomes. Working on niche market trends, opportunities, sales, and forecasted value is part of his skill set.
read more
Co-Author
Rahul Gotadki
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) Medical Device Databases and 510(k) Clearances, European Medicines Agency (EMA) Centralized Procedure Registers, Health Canada Medical Devices Active Licence Listing (MDALL), Japan Pharmaceuticals and Medical Devices Agency (PMDA) Medical Device Nomenclature, China National Medical Products Administration (NMPA) Medical Device Registration Database, and Brazil's ANVISA Medical Product Registry. Clinical and procedural data were gathered from the International Society for Aesthetic Plastic Surgery (ISAPS) Global Aesthetic Survey, American Society for Aesthetic Plastic Surgery (ASAPS) Cosmetic Surgery National Data Bank, American Society of Plastic Surgeons (ASPS) Procedural Statistics, American Med Spa Association (AmSpa) Industry Report, British Association of Aesthetic Plastic Surgeons (BAAPS) Annual Audit, and the German Federal Institute for Drugs and Medical Devices (BfArM) Medical Device Safety Reports. Medical literature and safety surveillance were accessed through the National Center for Biotechnology Information (NCBI/PubMed) Clinical Trials Registry, U.S. Centers for Disease Control and Prevention (CDC) National Health Statistics Reports, World Health Organization (WHO) Global Health Expenditure Database, National Library of Medicine (NLM) HSRR Database, and Cochrane Library Systematic Reviews on Cosmetic Interventions. Government health databases included the UK's National Health Service (NHS) Digital Hospital Episode Statistics, European Commission Eurostat Healthcare Data, Australian Therapeutic Goods Administration (TGA) Medical Device Incident Reports, and Korea Ministry of Food and Drug Safety (MFDS) Medical Device Information Portal. These sources were used to collect procedure statistics (surgical and non-surgical), regulatory approval data for injectables (botulinum toxins, dermal fillers) and energy-based devices, clinical safety studies, demographic adoption trends, and aesthetic clinic licensing landscape analysis.
Primary Research
Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. From aesthetic device manufacturers (laser, radiofrequency, ultrasound), injectable pharmaceutical companies, and aesthetic clinic chains, supply-side sources comprised CEOs, VPs of Business Development, regulatory affairs directors, and product managers. Board-certified plastic surgeons, aesthetic dermatologists, medical directors of aesthetic clinics, procurement managers from hospital cosmetic surgery departments, and operations managers from medical spas and beauty centers composed demand-side sources. Primary research has confirmed the product pipeline timelines for next-generation energy-based devices, validated market segmentation across invasive and non-invasive categories, and gathered insights on clinical adoption patterns for combination therapies, pricing strategies for premium injectables, and reimbursement dynamics for medically necessary versus cosmetic procedures.
Primary Respondent Breakdown:
• By Designation: C-level Primaries (40%), Director Level (35%), Others (25%)
• By Region: North America (40%), Europe (25%), Asia-Pacific (28%), Rest of World (7%)
Market Size Estimation
Global market valuation was derived through revenue mapping and procedure volume analysis across surgical and non-surgical aesthetics. The methodology included:
• The identification of over 50 main manufacturers in North America, Europe, Asia-Pacific, and Latin America, including botulinum toxin producers (Allergan, Galderma, Ipsen, Medytox, Hugel), dermal filler manufacturers, laser and energy-based device OEMS, and aesthetic clinic chains.
• Product mapping across invasive procedures (breast augmentation, liposuction, rhinoplasty, eyelid surgery, abdominoplasty) and non-invasive segments (Botox injections, soft tissue fillers, chemical peels, laser hair removal, microdermabrasion, radiofrequency devices)
• Analysis of reported and modeled annual revenues specific to aesthetics portfolios, including injectables, aesthetic devices, and procedure-based clinic revenues
• Coverage of manufacturers representing 70-75% of global market share in 2024
• Extrapolation using bottom-up (procedure volume × ASP by country/region segmented by surgical vs. non-surgical) and top-down (manufacturer revenue validation across device and pharmaceutical categories) approaches to derive segment-specific valuations. Additional triangulation was conducted using medical spa and clinic service revenue estimates, energy-based device unit shipment analysis, and injectable vial/syringe consumption models across key markets (US, Brazil, South Korea, Japan, Germany, UK, Australia)
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
Noah MalgeriCo-Founder
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
Joseph AguayoSales Operations & Pricing Manager
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
Peter Groot koerkampAccount and Business Manager
“Thank you, this will be very helpful for OQS.”
La Terria DoddProgram Support Specialist
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
Younghwan ChoiSenior Retail Manager
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile").
In general the report is well structured. Thanks very much for your efforts.”
Mark IrwinManagement Consultant
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
Rob KooikerGroup Product Manager HVAC & Fire Protection GMA
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
Akif MorogluStrategy & Business Development Director
“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”
Guilherme Gomes MartinsProduct Management Director